Plain-English translation of NCT07139509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new therapy called allogeneic umbilical cord blood-derived CAR-T cells, which are immune cells taken from donated cord blood and specially designed to fight multiple myeloma cancer cells. The study will check whether this treatment is safe and how well it works for people whose myeloma has come back or stopped responding to previous treatments. Researchers will follow participants closely for a year to watch for side effects and measure how the disease responds.
Multiple myeloma is a blood cancer that often comes back or becomes resistant to standard treatments, leaving patients with limited options. This medication represents a new approach—using specially engineered immune cells to target and destroy myeloma cells—and this trial will determine whether it is safe and effective for people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy (fludarabine and cyclophosphamide) over three days to prepare your body for the new treatment. After a two-day rest, you will receive an infusion of the new immune cells. Then you will return to the clinic for follow-up visits at day 28, and then at 1, 2, 3, 4, 6, 9, and 12 months after the infusion, where doctors will check how you are doing, monitor for side effects, and measure whether your myeloma is responding to the treatment.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China